Developer docs
API playgroundTry for free, no card

Search company profiles

CPC Biotech

Full company profile

uuid00228jx

Namestring
CPC Biotech
Websiteurl
cpcbiotech.it
Company typeenum
Private
Founded yearint
2006
Descriptiontext

CPC Biotech is a biopharmaceutical fluid management component supplier operating as a wholly-owned unit within Dover Corporation's Pump Solutions Group (PSG). The company was formally launched in April 2026 by merging the connector technology of CPC with the flow control expertise of PSG Biotech, repositioning the combined franchise as a single-source provider of sterile connectors, low-shear pumps, flow meters, and sensors for upstream and downstream biologic drug manufacturing as well as cell and gene therapy production.

The product portfolio centers on aseptic connection technology and flow control hardware. Flagship lines include the AseptiQuik G PPSU HT Series connectors made of BPA-free polyphenylsulfone, designed to withstand autoclave sterilization at 130°C and chemical exposure across pH 2-12 including sodium hydroxide, benzyl alcohol, and DMSO, and the MicroCNX Nano Series connectors engineered for robotic gripper manipulation to support sterile, human-free cell therapy production. The portfolio leverages Dover's manufacturing footprint across North America, Europe, and Asia to serve biopharmaceutical and cell therapy manufacturers in more than 50 countries.

CPC Biotech operates as a B2B industrial manufacturer, generating revenue through hardware sales of components to biopharmaceutical manufacturers via direct enterprise field sales and industrial distribution channels. The company made its public debut at INTERPHEX 2026 in New York City and announced a strategic co-development partnership with Multiply Labs in May 2026 to integrate MicroCNX connectors with robotic cell therapy automation systems.

Short descriptiontext

CPC Biotech supplies sterile connectors, low-shear pumps, flow meters, and sensors to biopharmaceutical manufacturers and cell therapy producers globally. Operating within Dover Corporation's Pump Solutions Group, the company serves biologic drug and cell therapy manufacturing customers across more than 50 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMonza, Italy
HQ citystring
Monza
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile connectors, aseptic connectors, biopharmaceutical components, fluid management systems, bioprocessing equipment
Industry2 codes
PRIMARYHLAAAJAC
Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Measuring, Dispensing, and Other Pumping Equipment Manufacturing333914
  • Plastics Pipe and Pipe Fitting Manufacturing326122
SIC code2 codes
  • Pumps & Pumping Equipment3561
  • Gaskets, Packg & Sealg Devices & Rubber & Plastics Hose3050
Product category
Biopharmaceutical Processing Equipment
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Component Sales
TypeHardware Sales
Description

CPC Biotech generates revenue through the sale of sterile connectors, low-shear pumps, flow meters, and sensors for the biopharmaceutical processing industry. The company serves as a combined entity merging CPC's connector technology with PSG Biotech's flow control expertise.

genengnews.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MicroCNX Nano Series
Description

Robot-optimized aseptic connectors for cell therapy manufacturing

prnewswire.com
+1 more record
Core offering1 text field

CPC Biotech manufactures and sells fluid management components for the biopharmaceutical industry, including sterile and aseptic connectors, low-shear pumps, flow meters, and sensors used in upstream and downstream biologic drug manufacturing and in cell and gene therapy production. The portfolio integrates CPC's connector technology with PSG Biotech's flow control expertise into a single-source offering for bioprocessing customers globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Improved scalability and affordability of cell therapies through robotic automation
+2 more records
Product overview1 text field

CPC Biotech operates as a comprehensive biopharmaceutical fluid management company, combining the connector technology of CPC with the flow control expertise of PSG Biotech under Dover Corporation's Pump Solutions Group. The portfolio includes the MicroCNX® Nano Series robot-optimized aseptic connectors (for automated cell therapy manufacturing), the AsepticQuik G PPSU HT Series high-temperature connectors, low-shear pumps, flow meters, and sensors. The company serves customers in more than 50 countries across North America, Europe, and Asia, focusing on upstream and downstream biologic drug manufacturing as well as cell and gene therapy production. The recent partnership with Multiply Labs extends the product line into robotic automation for cell therapy manufacturing, while the AsepticQuik G PPSU HT Series addresses high-temperature and chemically harsh bioprocess applications.

Product and service4 records
1MicroCNX Nano Series Aseptic Connectors
CategoryAseptic connectors
Description

Robot-optimized aseptic connectors designed for manipulation by robotic grippers, enabling sterile cell therapy production without human operators in automated cell therapy manufacturing workflows.

2AseptiQuik G PPSU HT Series Connectors
CategoryAseptic connectors
Description

High-temperature sterile connectors made of polyphenylsulfone (PPSU) for chemically harsh bioprocess applications, with BPA-free composition, pH 2-12 chemical resistance, and autoclave compatibility up to 130°C. Backward-compatible with existing AseptiQuik G products.

3Low-Shear Pumps
CategoryFlow control components
Description

Flow control pumps designed for sensitive biopharmaceutical fluid handling, providing low-shear transfer of biologic fluids in upstream and downstream bioprocessing.

4Flow Meters and Sensors
CategoryFlow measurement components
Description

Flow measurement and sensing components for biopharmaceutical processing, combined with connector technology to deliver an integrated fluid management solution for biologic drug manufacturing and cell and gene therapy production.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-27
Description

CPC Biotech partnered with Multiply Labs to develop robotic systems for cell therapy manufacturing automation. The collaboration centers on CPC Biotech's robot-optimized MicroCNX Nano Series aseptic connector designed for manipulation by robotic grippers, combined with Multiply Labs' robotic interface. Both companies aim to address manufacturing bottlenecks and contamination risks in cell therapy production while maximizing production capacity in compact footprints to enable scale and affordability.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CPC Biotech

Biopharmaceutical Processing Equipmentcpcbiotech.it

CPC Biotech supplies sterile connectors, low-shear pumps, flow meters, and sensors to biopharmaceutical manufacturers and cell therapy producers globally. Operating within Dover Corporation's Pump Solutions Group, the company serves biologic drug and cell therapy manufacturing customers across more than 50 countries.

What CPC Biotech does

CPC Biotech is a biopharmaceutical fluid management component supplier operating as a wholly-owned unit within Dover Corporation's Pump Solutions Group (PSG). The company was formally launched in April 2026 by merging the connector technology of CPC with the flow control expertise of PSG Biotech, repositioning the combined franchise as a single-source provider of sterile connectors, low-shear pumps, flow meters, and sensors for upstream and downstream biologic drug manufacturing as well as cell and gene therapy production.

The product portfolio centers on aseptic connection technology and flow control hardware. Flagship lines include the AseptiQuik G PPSU HT Series connectors made of BPA-free polyphenylsulfone, designed to withstand autoclave sterilization at 130°C and chemical exposure across pH 2-12 including sodium hydroxide, benzyl alcohol, and DMSO, and the MicroCNX Nano Series connectors engineered for robotic gripper manipulation to support sterile, human-free cell therapy production. The portfolio leverages Dover's manufacturing footprint across North America, Europe, and Asia to serve biopharmaceutical and cell therapy manufacturers in more than 50 countries.

CPC Biotech operates as a B2B industrial manufacturer, generating revenue through hardware sales of components to biopharmaceutical manufacturers via direct enterprise field sales and industrial distribution channels. The company made its public debut at INTERPHEX 2026 in New York City and announced a strategic co-development partnership with Multiply Labs in May 2026 to integrate MicroCNX connectors with robotic cell therapy automation systems.

CPC Biotech firmographics

Firmographics
Name
CPC Biotech
Website
https://cpcbiotech.it
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
CPC Biotech supplies sterile connectors, low-shear pumps, flow meters, and sensors to biopharmaceutical manufacturers and cell therapy producers globally. Operating within Dover Corporation's Pump Solutions Group, the company serves biologic drug and cell therapy manufacturing customers across more than 50 countries.
Ownership category
akta.pro rank

CPC Biotech industry classification

Industry
Product category
Biopharmaceutical Processing Equipment
NAICS
Measuring, Dispensing, and Other Pumping Equipment Manufacturing (333914), Plastics Pipe and Pipe Fitting Manufacturing (326122)
SIC
Pumps & Pumping Equipment (3561), Gaskets, Packg & Sealg Devices & Rubber & Plastics Hose (3050)
akta.pro industry
PRIMARYHLAAAJAC
Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Sterile connectors
  • Aseptic connectors
  • Biopharmaceutical components
  • Fluid management systems
  • Bioprocessing equipment

Where CPC Biotech is headquartered

Location

Headquarters

HQ city
Monza
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

CPC Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Biopharmaceutical Component Sales: CPC Biotech generates revenue through the sale of sterile connectors, low-shear pumps, flow meters, and sensors for the biopharmaceutical processing industry. The company serves as a combined entity merging CPC's connector technology with PSG Biotech's flow control expertise.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

CPC Biotech product offering

Product offering

Core offering

CPC Biotech manufactures and sells fluid management components for the biopharmaceutical industry, including sterile and aseptic connectors, low-shear pumps, flow meters, and sensors used in upstream and downstream biologic drug manufacturing and in cell and gene therapy production. The portfolio integrates CPC's connector technology with PSG Biotech's flow control expertise into a single-source offering for bioprocessing customers globally.

Product overview

CPC Biotech operates as a comprehensive biopharmaceutical fluid management company, combining the connector technology of CPC with the flow control expertise of PSG Biotech under Dover Corporation's Pump Solutions Group. The portfolio includes the MicroCNX® Nano Series robot-optimized aseptic connectors (for automated cell therapy manufacturing), the AsepticQuik G PPSU HT Series high-temperature connectors, low-shear pumps, flow meters, and sensors. The company serves customers in more than 50 countries across North America, Europe, and Asia, focusing on upstream and downstream biologic drug manufacturing as well as cell and gene therapy production. The recent partnership with Multiply Labs extends the product line into robotic automation for cell therapy manufacturing, while the AsepticQuik G PPSU HT Series addresses high-temperature and chemically harsh bioprocess applications.

Differentiator

Problem solved

Functional benefit

Brands

  • MicroCNX Nano Series: Robot-optimized aseptic connectors for cell therapy manufacturing
  • AseptiQuik G PPSU HT Series

Products and services

  • MicroCNX Nano Series Aseptic Connectors Robot-optimized aseptic connectors designed for manipulation by robotic grippers, enabling sterile cell therapy production without human operators in automated cell therapy manufacturing workflows.
  • AseptiQuik G PPSU HT Series Connectors High-temperature sterile connectors made of polyphenylsulfone (PPSU) for chemically harsh bioprocess applications, with BPA-free composition, pH 2-12 chemical resistance, and autoclave compatibility up to 130°C. Backward-compatible with existing AseptiQuik G products.
  • Low-Shear Pumps Flow control pumps designed for sensitive biopharmaceutical fluid handling, providing low-shear transfer of biologic fluids in upstream and downstream bioprocessing.
  • Flow Meters and Sensors Flow measurement and sensing components for biopharmaceutical processing, combined with connector technology to deliver an integrated fluid management solution for biologic drug manufacturing and cell and gene therapy production.

Quantifiable outcome

  • Improved scalability and affordability of cell therapies through robotic automation
  • +2 more outcomes

Companies that use CPC Biotech

Customer profile

Segments2 records

Ideal customer profiles2 records

CPC Biotech technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CPC Biotech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Multiply LabscoreStrategic or Co-development Partner · 27 May 2026CPC Biotech partnered with Multiply Labs to develop robotic systems for cell therapy manufacturing automation. The collaboration centers on CPC Biotech's robot-optimized MicroCNX Nano Series aseptic connector designed for manipulation by robotic grippers, combined with Multiply Labs' robotic interface. Both companies aim to address manufacturing bottlenecks and contamination risks in cell therapy production while maximizing production capacity in compact footprints to enable scale and affordability.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

CPC Biotech competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

CPC Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CPC Biotech leadership team

Management profile

Number of profiles

Profiles1 record

CPC Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CPC Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CPC Biotech

What does CPC Biotech do?

CPC Biotech manufactures and sells fluid management components for the biopharmaceutical industry, including sterile and aseptic connectors, low-shear pumps, flow meters, and sensors used in upstream and downstream biologic drug manufacturing and in cell and gene therapy production. The portfolio integrates CPC's connector technology with PSG Biotech's flow control expertise into a single-source offering for bioprocessing customers globally.

Is CPC Biotech a public or private company?

CPC Biotech is a private company. It is classified as corporate owned and is currently operating.

When was CPC Biotech founded?

CPC Biotech was founded in 2006. It employs 11 to 50 people.

Where is CPC Biotech based?

CPC Biotech is headquartered in Monza, Italy, in the Europe region.

How does CPC Biotech make money?

One revenue line is on record: biopharmaceutical Component Sales.

Does CPC Biotech have an API?

No public API is recorded for CPC Biotech.

What industry is CPC Biotech in?

CPC Biotech's product category is Biopharmaceutical Processing Equipment. Its primary akta.pro industry code is HLAAAJAC, Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors), with a secondary code of HLAGAGAG, Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP). Its NAICS code is 333914 and its SIC code is 3561.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestDover Q2 Preview: What to Watch in the $8 Billion Five-Segment PortfolioDover Corporation is scheduled to report its Q2 2026 earnings on June 16, 2026, testing whether its $8 billion five-segment industrial portfolio justifies a premium valuation as an adaptive platform rather than a broad-based manufacturer. Recent developments across segments include Dover Fueling Solutions launching a crypto payment platform in EMEA, MPG introducing new aerospace and defense products, SWEp expanding capacity for AI data-center demand, CPC Biotech advancing cell-therapy automation, and Markem-Imaje releasing CoLOS Version 7 for industrial coding. Investors will assess cross-segment performance breadth, margin resilience from sticky revenue streams, and whether management frames recent product launches as coordinated platform evolution or isolated tactical updates.MorningstarCPC Biotech Introduces One-Inch Flow Path, Single-Use Sterile Disconnect for BioprocessingCPC Biotech has launched the RevolveSD Series, a one-inch single-use sterile disconnect designed to simplify bioprocessing tasks. The device allows operators to disconnect tubing in seconds without special equipment, reducing setup time and preventing unintended reconnection risks. Made from durable polyphenylsulfone, the connector features dual-valve non-spill technology and supports smooth bidirectional flow for large-scale applications.Investing.comCPC Biotech partners with Multiply Labs on cell therapy robots By Investing.comCPC Biotech, part of Dover Corporation, announced a collaboration with Multiply Labs to develop robotic systems for cell therapy manufacturing, combining CPC Biotech's MicroCNX Nano Series aseptic connectors with Multiply Labs' robotic interface designed for manipulation by robotic grippers. The companies aim to address manufacturing bottlenecks and contamination risks in cell therapy production, which currently relies entirely on manual processes. Both companies are focused on maximizing production capacity in a compact footprint to enable scale and affordability in cell therapy manufacturing.Investing.comCPC Biotech partners with Multiply Labs on cell therapy robots By Investing.comCPC Biotech, a subsidiary of Dover Corporation operating within the Pump Solutions Group, announced a collaboration with Multiply Labs to develop robotic systems for cell therapy manufacturing. The companies are creating an aseptic connector designed for robotic operation, combining CPC Biotech's MicroCNX Nano Series connectors with Multiply Labs' robotic interface, to address manufacturing bottlenecks and contamination risks in cell therapy production. Multiply Labs' CEO noted that current cell therapy manufacturing is entirely manual, and robotic automation could enable scale and affordability previously unattainable through manual approaches.Stock TitanCPC Biotech, Multiply Labs team on cell therapy robotsCPC Biotech, a manufacturer of connectors and flow sensors for biopharmaceutical processing and part of Dover Corporation, has announced a collaboration with San Francisco-based Multiply Labs to advance robotic automation in cell therapy manufacturing. The partnership will focus on developing CPC Biotech's first robot-optimized aseptic connector, combining the MicroCNX Nano Series with a proprietary interface designed for robotic manipulation to enable sterile cell therapy production without human operators. Both companies aim to reduce manufacturing bottlenecks, minimize contamination risks, and improve the scalability and affordability of cell therapies through this modular robotic approach.PR NewswireCPC Biotech Collaborates with Multiply Labs to Advance Cell Therapy AutomationCPC Biotech, a manufacturer of biopharmaceutical processing components owned by Dover Corporation, has partnered with Multiply Labs to develop robotic systems for cell therapy manufacturing automation. The collaboration centers on CPC Biotech's new robot-optimized MicroCNX® Nano Series aseptic connector designed for manipulation by robotic grippers, addressing the challenge of automating traditionally manual cell therapy production. Both companies aim to maximize production capacity in compact footprints while improving reliability, repeatability, and scalability to make advanced therapies more accessible and affordable.AijournCPC Biotech Launches Versatile AseptiQuik G ConnectorCPC Biotech, a manufacturer of connectors and flow control components for biopharmaceutical processing, announced the launch of the AseptiQuik G PPSU HT Series connectors designed for high-temperature and chemically harsh bioprocess applications. The new connectors are made of BPA-free polyphenylsulfone material that withstands a pH range of 2-12 and is compatible with both gamma and autoclave sterilization methods, offering broader chemical compatibility than traditional polymers. The connectors are available in multiple sizes for hose barbs and sanitary fittings, and are backward-compatible with existing AseptiQuik products, requiring no additional operator training.Stock TitanCPC Biotech adds PPSU sterile connectorsCPC Biotech, a subsidiary of PSG and Dover Corporation (NYSE: DOV), announced the launch of the AseptiQuik G PPSU HT Series sterile connectors on April 20, 2026. The new connectors are made of polyphenylsulfone (PPSU), are BPA-free, withstand pH 2-12 and harsh chemicals including sodium hydroxide, benzyl alcohol, and DMSO, and support both gamma and autoclave sterilization up to 130 degrees Celsius. The product is available in multiple sizes for hose barbs and sanitary fittings, and is backward-compatible with existing AseptiQuik connector lines.PR NewswireCPC Biotech Launches Versatile AseptiQuik G ConnectorCPC Biotech, a manufacturer of connectors and flow control components for biopharmaceutical processing and part of Dover Corporation (NYSE: DOV), has launched the AseptiQuik G PPSU HT Series connectors. The new connectors are made of durable polyphenylsulfone (PPSU), are BPA-free, and offer enhanced chemical compatibility including resistance to a wide pH range and harsh chemicals such as sodium hydroxide, benzyl alcohol, and DMSO, while also withstanding autoclave sterilization temperatures up to 266°F/130°C. The connectors are available in multiple sizes and are backward-compatible with existing AseptiQuik G products, requiring no additional operator training.GenengnewsCPC Biotech Launched to Offer a Fluid Management Component PortfolioCPC Biotech was launched as a combined entity merging the connector technology of CPC with the flow control expertise of PSG Biotech, operating as part of PSG to serve as a single source for sterile connectors, low-shear pumps, flow meters, and sensors for the biopharma industry. The new company will drive innovation in upstream and downstream biologic drug manufacturing as well as cell and gene therapy production, with manufacturing facilities across North America, Europe, and Asia and customers in more than 50 countries. CPC Biotech plans its public debut at INTERPHEX 2026, taking place April 21–23 at the Jacob K. Javits Convention Center in New York City.